Caregiver Resource
A Caregiver’s Guide to Tracking
Medication Changes in Drug-Resistant Epilepsy
A structured guide for caregivers on tracking and documenting anti-seizure medication changes using observation and organized data to share with your care team.
In This Guide
Key Principles
Low & Slow Titration
Allows the body to adjust; reduces side effect risk.
Observe, Don't Rush
Short evaluation windows (<4 weeks) are statistically unreliable due to seizure clustering.
Track Quantitative Metrics
Seizure counts, rescue meds, sleep, behavior, appetite — provides objective signals.
Aim for Optimal Dose, Not Maximum Dose
Your neurologist balances benefits and side effects; tracking helps document both sides of that equation.
Use Longer Observation Windows
≥4 weeks per dose change allows stabilization and reduces random noise in seizure patterns.
Data > Emotion
Decisions based on trends over time, not single seizure events.
Dose Evaluation Workflow
Why low and slow matters: Each dose change requires an acclimation period — typically at least one week, depending on the medication’s half-life — before the body reaches a new steady state. Only after acclimation should you begin tracking the true response. By titrating in small increments and allowing time to stabilize, you can isolate the effect of each change and catch emerging side effects early, before they compound at higher doses.
Step 1
Baseline Tracking (≥4 weeks)
- Log seizure frequency, duration, type, triggers
- Record sleep, appetite, behavior
Step 2
Dose Change (Titration)
- Increase/decrease slowly (small increments)
- Allow 1 week for physiologic stabilization
Step 3
Observation Window (≥3 additional weeks)
- Continue all metric tracking
- Visualize trends to detect true response vs random fluctuation
Step 4
Assessment
- Compare logged pre- and post-dose data
- Bring organized data to your neurologist to discuss how the dose change looks in the logs
Step 5
Repeat Only After Stable Observation
- Avoid premature dose changes
- Preserve medication options for lifelong care
What 14 years of drug-resistant epilepsy has taught us
We treat every medication the same way. We start at — or sometimes below — the recommended starting dose, measure for a month, and evaluate. If a seizure cluster occurs, we may increase, but the increment can be very small. Sometimes we learned that an increase of just 0.2 mg was enough to reach the next period of stability. It can take years to reach a maximum dose when you’re measuring at every level along the way — and that’s the point.
Expect every medication to honeymoon. In drug-resistant epilepsy, a “honeymoon period” is a temporary window of improved seizure control after a dose change, followed by a gradual return toward baseline. This happens with nearly every medication. Because honeymoons end, you need to preserve your options and go slow. Burning through medications quickly means you may have nothing left when the next honeymoon fades.
Tracking Metrics
| Date Range | Total Seizures | Seizure Days | Seizure-Free Days | Seizures/Day | Avg Length (sec) | Rescue Meds | Active Medications |
|---|---|---|---|---|---|---|---|
| Jan 1 – Jan 28 | 18 | 12 | 16 | 0.64 | 45.2 | 3 | Clobazam 10mg |
| Jan 29 – Feb 25 | 14 | 10 | 18 | 0.50 | 38.5 | 2 | Clobazam 15mg |
| Feb 26 – Mar 25 | 9 | 7 | 21 | 0.32 | 30.1 | 1 | Clobazam 15mg |
| Mar 26 – Apr 22 | 11 | 8 | 20 | 0.39 | 32.8 | 2 | Clobazam 20mg |
These are the same metrics returned by the N1 Precision Insights date range report. Use the Reporting page to compare periods side-by-side and spot trends across dose changes.
Daily Events & Quality of Life
Track daily events that affect quality of life — sleep quality, mood, appetite, energy levels, and behavioral observations. These metrics paint a complete picture of how your child is doing beyond seizure counts alone.
Medications & Rescue Use
Log all active medications with dosages, track rescue medication use with timestamps, and record supplements. Every intervention is captured so you can view logged changes alongside outcomes across any date range.
Track Anything You Think Matters
Supplements, dietary changes, Epsom salt baths, CBD oil, essential oils — if you think it could make a difference, you can track it. Run a date range report and review the logged data alongside seizure entries. Organized data makes for better conversations with your care team.
Data Quality Is Everything
Every Day Must Be Logged
Each day requires an entry — either a seizure log or a seizure-free day. It is never assumed. A missing day is not the same as a seizure-free day. If it wasn’t recorded, it didn’t happen as far as the data is concerned. Gaps in logging create gaps in understanding.
No Data In, No Results Out
Reports, trend charts, and date range comparisons are only as useful as the data feeding them. If you track for three days and skip four, the weekly summary is meaningless. Consistent daily logging is the minimum requirement for any analysis to be trustworthy.
Data Quality Issues Create Real Problems
Incomplete entries, missed days, and inconsistent logging distort the data you share with your neurologist. A seizure count that looks low because days were skipped can give an incomplete picture — and incomplete data makes for incomplete conversations.
Built-In Quality Checks
N1 Precision Insights includes data quality checks that identify missing days, gaps in logging, and inconsistencies in your records. These tools exist because the quality of your data is the most important factor in having informed conversations with your neurologist.
Never assume — always record
A seizure-free day is just as important to log as a seizure day. It confirms that the day was observed and accounted for. The absence of a seizure is data. The absence of an entry is a gap. Treat every unlogged day as a problem to fix, not a day to skip.
Data Visualization Tools for Caregivers
Statistical Analysis
Averages, medians, and standard deviations summarize your logged data into numbers that help you and your neurologist discuss whether logged patterns changed after a dose adjustment.
Regression Analysis
Trend lines help visualize whether logged seizure frequency is gradually increasing, decreasing, or holding steady over time — giving you and your care team a clearer picture.
Bollinger Bands
Borrowed from financial analysis, Bollinger Bands draw a “typical range” around your logged data. When logged activity falls outside the band, it highlights a change worth discussing with your neurologist.
Clustering & Pattern Detection
Grouping logged seizure events by shared characteristics — time of day, triggers, type, or proximity to dose changes — helps organize data in ways that are easier to review with your care team.
Trend Monitoring
Rolling averages of your logged data can highlight when logged seizure activity is trending upward — giving you organized data to bring to your neurologist sooner.
AI-Assisted Summaries
AI generates summaries of your logged data to help you organize observations and prepare for appointments. These summaries are starting points for discussion with your care team — not medical advice, but organized data worth reviewing.
About advanced features: Many of these visualization tools require significant computational resources to run. Some advanced features will carry a cost to cover the infrastructure behind them. Our goal is to make structured data visualization available to every family — not just those with technical expertise.
Understanding the Dose-Response Curve
Subtherapeutic
Dose too low — seizures remain uncontrolled. Increasing the dose is likely to improve seizure control without significant side effects.
Optimal Therapeutic Window
Maximum seizure control with minimal side effects. This is the target zone where the medication provides the best risk-to-benefit ratio.
Excess Dose
Side effects outweigh benefits — may reduce quality of life through increased sedation, cognitive impairment, or behavioral changes.
Visualizing this curve helps families and clinicians identify the true optimal dose rather than defaulting to the maximum tolerated dose.
The Dose-Response Curve
Why This Matters
Without data, dose decisions rely on intuition. The optimal dose is where the gap between seizure control and side effects is largest — not where either curve peaks.
A Data-Driven Approach
Track seizure frequency, rescue medication use, and quality-of-life metrics at each dose level. Compare date ranges in your reports to see exactly where you sit on this curve.
Recognize the Crossover Point
When side effects start rising faster than seizure control improves, you’ve passed the optimal window. Trending data across dose changes reveals this inflection point.
Every Patient Is Different
These curves shift for every individual. Only consistent tracking over time can reveal where your child’s unique optimal window lies.
The Cost of Moving Too Fast
Medications Are a Limited Resource
There are only a handful of anti-seizure medications approved or used off-label for drug-resistant epilepsy. Once a medication is trialed and abandoned, it is rarely revisited. Cycling through options too quickly shrinks the list of available treatments for a condition that requires lifelong management.
You Can’t Evaluate What You Don’t Observe
Rapid titration makes it impossible to know whether a medication was actually ineffective or simply never given a fair trial. Without a proper observation window, a medication that could have helped may be discarded based on incomplete data — a decision that can’t be undone.
Compounding Side Effects Cause Real Harm
Escalating doses too fast can trigger severe side effects — sedation, cognitive regression, behavioral changes, or paradoxical seizure worsening. These effects may take weeks to resolve after the dose is reduced, and some long-term impacts on development and cognition may not be fully reversible.
Crisis Mode vs. Steady-State Decisions
During a seizure emergency, rapid intervention is appropriate. But ongoing maintenance dosing should never be driven by crisis-mode urgency. Rushed dose changes outside of acute situations lead to reactive, emotional decisions rather than informed, data-driven ones.
Protect the options you have left
Every medication deserves a structured trial with adequate time to acclimate, a clear observation window, and documented metrics. Moving too fast doesn’t just risk today’s stability — it narrows the options available for the rest of your child’s life. Patience and data are how you preserve those options.
Communication Tips for Families
Define Success Up Front
“Can we define what counts as success before changing doses?”
Ask About Optimal Dose
“How will we know this dose is optimal, not just the maximum tolerated?”
Request a Fair Trial
“We want to make sure the medication has a fair trial and that side effects are minimized.”
Present Data, Not Emotions
Share charts and trends over 4–8 weeks rather than reporting a single bad day or isolated seizure event.
Discuss Observation Windows
“Can we give this dose at least 4 weeks before deciding whether it’s working?”
Clarify Side Effect Trade-offs
“At what point do side effects outweigh the benefit of fewer seizures?”
Ask About the Long-Term Plan
“If this dose doesn’t work, what are our next options and how do we preserve them?”
Bring Your Reports
Print or share your N1 Precision Insights date range reports so your neurologist can see the same data you see.
Setting Realistic Expectations
Seizures Are Part of This Condition
With drug-resistant epilepsy, seizures persist despite adequate trials of appropriate medications. Unlike some epilepsies that can be controlled or outgrown, drug-resistant epilepsy means seizures will be an ongoing reality. Accepting this is not giving up — it’s the foundation for making better decisions.
Seizure Freedom Is a Dream, Not a Benchmark
Every family hopes for seizure freedom, and that hope matters. But for many drug-resistant epilepsy patients, zero seizures is not a realistic treatment target. When seizure freedom becomes the only acceptable outcome, it drives aggressive dosing that can cause more harm than the seizures themselves.
Quality of Life Is the Real Measure
The true goal is not the lowest possible seizure count at any cost. It’s the best possible life — where your child is alert, engaged, developing, and present. A child with occasional seizures and a good quality of life is better off than one who is seizure-reduced but sedated, withdrawn, or cognitively impaired.
Reframe the Question
Instead of asking “How do we stop all seizures?” ask “At what dose does my child have the best balance of seizure control, side effects, and quality of life?” That shift in framing changes every conversation with your care team and every conversation with your care team you make together.
Redefine What “Failure” Means
When a medication is declared a failure, ask: failure by what measure? In an intractable condition, every medication will eventually fall short of seizure freedom. But that doesn’t mean it provided no benefit. Perhaps the dosing protocol moved too fast and missed the optimal window entirely. Perhaps the medication was never given a fair trial. Labeling a medication as “failed” without structured data to back that conclusion is not evidence — it’s assumption.
Benefits Hide in the Details
There are so many variables in seizure management that benefit is not always obvious. Maybe seizure counts stayed the same but average duration shortened. Maybe rescue medication use dropped. Maybe seizure-free stretches grew longer even though clusters still occurred. Without granular data across every metric, these improvements are invisible — and a medication that was actually helping gets discarded. A data-driven approach is the only way to know exactly whether there was a benefit or not.
Every “failed” medication deserves a second look
If you’ve been told three medications have failed, consider whether the data existed to support that conclusion. Were observation windows long enough? Were increments small enough? Were all metrics — not just seizure count — evaluated? In drug-resistant epilepsy, the difference between a failed medication and an under-evaluated one can be the difference between having treatment options and running out of them.
N-of-1: Every Patient Is Unique
What N-of-1 Means
The concept of N-of-1 means focusing on one individual rather than population averages. Because every drug-resistant epilepsy patient responds differently, your own logged data is the most relevant record to share with your neurologist.
Why Drug-Resistant Epilepsy Demands It
Drug-resistant epilepsy accounts for roughly one-third of all epilepsy diagnoses. Each patient’s seizure phenotype, underlying etiology, and drug metabolism are functionally unique. Population-level dosing guidelines simply cannot account for this variability.
Standard Epilepsy Dosing Doesn’t Apply
In common epilepsies, clinicians follow well-studied dose ranges validated across large populations. Drug-resistant epilepsy patients often respond unpredictably — a dose that helps one patient may worsen seizures in another. Some medications that work for common epilepsies may be ineffective or even counterproductive.
Polytherapy Adds Complexity
Most drug-resistant epilepsy patients are on multiple medications simultaneously. Drug interactions, cumulative side effects, and competing mechanisms make it impossible to predict the right combination from population data alone. Each adjustment is an experiment that requires careful observation.
Your Data Is the Record
Consistently logging seizures, rescue medication use, and quality-of-life observations builds the organized record that your neurologist needs to have informed conversations about next steps.
Structured Tracking Is the Method
An N-of-1 approach doesn’t mean guessing — it means structured, consistent tracking for one individual. Baseline periods, documented dose changes, observation windows, and data comparison are the tools that turn subjective impressions into organized records for your care team.
The bottom line
Your child is not a statistic in someone else’s study. Their individual response matters most. The tracking framework above exists because standard approaches were designed for populations — not for the individual complexity of drug-resistant epilepsy. Track rigorously, observe patiently, and bring organized data to every conversation with your care team.
Take Ownership of Your Child's Care
Daily Tracking Changes Everything
Most families track seizures loosely — a note here, a memory there. But consistent, daily logging is the single most powerful tool you have. It transforms scattered observations into clear trends that reveal what’s actually working and what isn’t.
Analysis Is What No One Does
Logging data is only half the equation. Reviewing it — comparing date ranges, spotting patterns, identifying when a medication change helped or hurt — is where the real insights live. This is the step most families skip, and it’s the one that matters most.
You Are Your Child’s Best Advocate
Your neurologist sees your child for minutes at a time, weeks or months apart. You see them every day. When you walk into an appointment with structured data — seizure counts, rescue use, side effect trends — you shift the conversation from anecdotes to organized data. That changes the quality of the conversation.
Try Something New
If the current approach isn’t producing results, it’s time to change the process. Commit to daily tracking, give each dose change a full observation window, and bring your reports to every appointment. A data-driven approach is how you take control in a condition where so much feels out of your hands.
Your child’s data matters
You don’t need a research lab. You need consistency, patience, and the right tools. Track every day. Review every week. Share every report. The data you log today helps shape better conversations with your care team tomorrow.
Why This Exists
The Dartboard Approach
In traditional epilepsy management, dosing often follows a “dartboard approach” — try a medication, see what happens, and if seizures persist, throw another dart. Doses are adjusted based on brief clinic visits, short-term impressions, and gut instinct rather than structured data. Medications are started, ramped up quickly, declared failures, and abandoned — all without enough observation time to know whether they ever had a chance to work.
Born from a Parent’s Experience
This system was created by a parent of a child with drug-resistant epilepsy after years of watching the dartboard approach produce inconsistent results and unnecessary side effects. The question was simple: why are we guessing when we could be measuring? That question became a mission — to replace guesswork with data-informed decisions.
8 Years in the Making
N1 Precision Insights has been in development for over eight years. More than 2,000 hours went into building the prototype alone — designing the data models, developing the analytics, and refining the workflows that make structured dose evaluation practical for everyday caregivers.
Replacing Guesswork with Organized Data
Every feature in this platform exists because the dartboard approach left a gap. Date range comparisons exist because clinics rely on memory. Data quality checks exist because missed days distort the picture. Structured views exist because “I think it’s better” is not a useful record. This system was built to give families the tools that should have existed all along.
A complete history, protected and preserved
From day one, we have tracked every dosage change and every seizure for our own child. The result is a complete, unbroken picture of his entire medical history — something no clinic visit summary or handwritten log could replicate. The appropriate safeguards are in place to store and protect that data, and those protections will continue to strengthen as the platform evolves.
N1 Precision Insights is not a side project and it is not going anywhere. This application will continue to be developed, refined, and expanded — because the families who depend on it deserve a tool that grows with their child’s needs, not one that disappears.
Built Complex Because Your Child Is Worth It
Oversimplifying this process means things get missed. A seizure log that only tracks counts leaves out duration, type, triggers, rescue use, side effects, and quality of life — all of which matter for conversations with your care team. N1 Precision Insights is the most comprehensive seizure tracking journal available because the complexity of drug-resistant epilepsy demands it.
This platform will continue to be refined and expanded as we learn more — from the data, from the research, and from the families using it every day. Better tools lead to better data. Better data leads to better conversations with your care team. And better conversations lead to better outcomes for your child.
A Long-Term Goal: From N of 1 to N of Many
N of 1 is the foundation — rigorous, structured tracking for your child. N of Many is the future — when hundreds of families contribute the same quality of data, patterns emerge that no single family or clinical trial could reveal alone.
Strength in Numbers
If even 500 families with drug-resistant epilepsy tracked their child’s medication responses with the same structured approach, the resulting dataset would be unlike anything that exists in epilepsy research today — real-world, longitudinal, and granular enough to reveal patterns that clinical trials with small sample sizes cannot.
Identifying Sub-Populations
Not all drug-resistant epilepsy patients respond to medications the same way. Machine learning models — such as random forest classifiers paired with clustering algorithms — can analyze medication response data across hundreds of patients to identify sub-populations that share similar response profiles. Groups of children who respond well to the same medications may share characteristics that are invisible without large-scale data analysis.
Combining Genetic & Response Data
With over 1,800 known SCN1A mutations, correlating specific genetic variants with real-world medication response data could reveal which mutations predict better outcomes on which drugs. Layering genetic profiles onto treatment response clusters brings precision medicine closer to reality for a condition that has never had it.
Redefining Early Treatment Protocols
The ultimate goal is to change what happens at diagnosis. Instead of every newly diagnosed child starting the same trial-and-error process, clinicians could reference sub-population data to select medications with the highest likelihood of benefit for that child’s specific profile — reducing years of unnecessary experimentation and preserving treatment options from the start.
Share your data, shape the future
As this platform grows, we plan to enable voluntary sharing of aggregated, de-identified data for research purposes. Making real-world logged data available to researchers could help advance understanding of drug-resistant epilepsy and inform future research. We will never sell your data. But if you choose to share it, your child’s experience could help the next generation. If you are a researcher interested in drug-resistant epilepsy data, reach out — we are open to working together on data-sharing arrangements tailored to your study’s needs.
Goal
Help families build organized, structured health records that support individualized, informed conversations with their care teams about drug-resistant epilepsy.
N1 Precision Insights is a personal health journaling and data visualization tool. It is not a medical device and does not provide medical advice, diagnosis, or treatment recommendations. All dosing and medication decisions should be made by your neurologist or healthcare provider. The information on this page is educational content for caregivers — not clinical guidance. Data visualizations reflect only what you have logged and are not validated for clinical accuracy.